StockData
Crescent Biopharma, Inc. logo

Crescent Biopharma, Inc. (CBIO) stock

CBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$13.04−0.46 (-3.41%)

Close on Nov 17, 2026Market cap $484.36MP/E –Yield –

Crescent Biopharma operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Crescent Biopharma's operating income for the twelve months ending Jun 30, 2026 was -$168.47M. For fiscal 2025 it was -$152.63M. The highest annual figure on record is $3.64M in fiscal 2012.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$152.63M–
FY2024Dec 31, 2024-$40.04M–
FY2023Dec 31, 2023-$39.28M–
FY2022Dec 31, 2022-$47.40M–
FY2021Dec 31, 2021-$63.45M–
FY2020Dec 31, 2020-$51.51M–
FY2019Dec 31, 2019-$61.39M–
FY2018Dec 31, 2018-$51.50M–
FY2017Dec 31, 2017-$33.93M–
FY2016Dec 31, 2016-$31.91M–
FY2015Dec 31, 2015-$12.78M–
FY2014Dec 31, 2014-$11.14M–
FY2013Dec 31, 2013-$10.61M-391.8%
FY2012Dec 31, 2012$3.64M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$26.36M–
Q1 FY2026Mar 31, 2026-$24.73M–
Q4 FY2025Dec 31, 2025-$91.49M–
Q3 FY2025Sep 30, 2025-$25.89M–
Q2 FY2025Jun 30, 2025-$21.03M–
Q1 FY2025Mar 31, 2025-$14.22M–
Q4 FY2024Dec 31, 2024-$7.33M–
Q3 FY2024Sep 30, 2024-$11.23M–
Q2 FY2024Jun 30, 2024-$10.36M–
Q1 FY2024Mar 31, 2024-$11.12M–
Q4 FY2023Dec 31, 2023-$9.59M–
Q3 FY2023Sep 30, 2023-$9.81M–
Q2 FY2023Jun 30, 2023-$8.93M–
Q1 FY2023Mar 31, 2023-$10.94M–
Q4 FY2022Dec 31, 2022-$10.62M–
Q3 FY2022Sep 30, 2022-$8.77M–
Q2 FY2022Jun 30, 2022-$13.35M–
Q1 FY2022Mar 31, 2022-$14.66M–
Q4 FY2021Dec 31, 2021-$17.43M–
Q3 FY2021Sep 30, 2021-$17.34M–
Q2 FY2021Jun 30, 2021-$14.40M–
Q1 FY2021Mar 31, 2021-$14.28M–
Q4 FY2020Dec 31, 2020-$15.57M–
Q3 FY2020Sep 30, 2020-$13.73M–
Q2 FY2020Jun 30, 2020-$14.11M–
Q1 FY2020Mar 31, 2020-$8.11M–
Q4 FY2019Dec 31, 2019-$15.34M–
Q3 FY2019Sep 30, 2019-$14.11M–
Q2 FY2019Jun 30, 2019-$16.82M–
Q1 FY2019Mar 31, 2019-$15.13M–
Q4 FY2018Dec 31, 2018-$14.96M–
Q3 FY2018Sep 30, 2018-$12.52M–
Q2 FY2018Jun 30, 2018-$12.15M–
Q1 FY2018Mar 31, 2018-$12.15M–
Q4 FY2017Dec 31, 2017-$9.54M–
Q3 FY2017Sep 30, 2017-$8.18M–
Q2 FY2017Jun 30, 2017-$8.24M–
Q1 FY2017Mar 31, 2017-$7.97M–
Q4 FY2016Dec 31, 2016-$8.36M–
Q3 FY2016Sep 30, 2016-$7.89M–

More Crescent Biopharma figures

See a number that looks wrong?